Roche, Glaxo add psychiatric behavior warnings to flu drugs

03/5/2008 | Guardian (London), The

Roche Holding and GlaxoSmithKline PLC -- manufacturers of Tamiflu and Relenza, respectively -- have placed new warnings regarding delirium and abnormal psychiatric behavior on the labels of their influenza medications. The FDA has reviewed reports of neuropsychiatric problems in some patients, primarily in Japan. The drugmakers, however, said on the labels that their drugs' link to these adverse reactions "has not been established."

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Director, Payer Marketing
Avalere Health
Washington, DC
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX